Schneider Jennifer
SEC CIK 1783060 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | Dir | 2,190 | — | — | 4 | 2024-05-15 | 2026-05-01 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
| 16 | Schneider Jennifer | Dir | — | — |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-05 17:29 | 2026-05-01 | VRTX | Vertex Pharmaceuticals | Schneider Jennifer | Dir | A - Grant | $0.00 | +472 | 2,190 | +27% | $0 |
| D | 2026-05-05 17:29 | 2026-05-01 | VRTX | Vertex Pharmaceuticals | Schneider Jennifer | Dir | D - Sale to Iss | — | -796 | 1,394 | -36% | — |
| 2025-05-05 | 2025-05-01 | VRTX | Vertex Pharmaceuticals | Schneider Jennifer | Dir | A - Grant | $0.00 | +796 | 1,718 | +86% | $0 | |
| 2024-05-17 | 2024-05-15 | VRTX | Vertex Pharmaceuticals | Schneider Jennifer | Dir | A - Grant | $0.00 | +922 | 922 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations